Crispr Therapeutics AG vs Vistra Corp — how do they compare? Crispr Therapeutics AG trades at $51.44 (market cap $4.88B), while Vistra Corp trades at $158.3 (market cap $52.41B). The key difference: Vistra Corp is far larger — about 10.7× Crispr Therapeutics AG's market cap, and Vistra Corp pays a 0.59% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Vistra Corp for 32 Days on average.
| CRSP | VST | |
|---|---|---|
Market Cap | $4.88B | $52.41B |
Volume | 2,861,747 | 11,278,074 |
Sector | Health | Utilities |
52-Week High | $74.92 | $210.85 |
52-Week Low | $44.34 | $134.71 |
Typical Hold Time | 77 Days | 32 Days |
Enterprise Value | $3.30B | $74.34B |
Dividend Yield | — | 0.59% |
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $52.35, down 3.06% on the day, with a bearish technical signal and negative profitability metrics. The company reported no revenue in 2025 with a net loss of $581.60M, though recent earnings beat expectations in Q2 2026. Analyst sentiment remains positive with a $67.83 price target and 57.9% buy ratings, supported by upcoming clinical data catalysts for its gene-editing therapies.
The stock faces significant fundamental challenges with negative margins and cash burn, but strong analyst support and pipeline progress offer long-term potential. Key risks include clinical trial outcomes and commercialization execution, while institutional interest and positive media coverage provide near-term catalysts for investor consideration.
Vistra Corp (VST) trades at $166.72, up 3.88% with strong analyst support (91% buy ratings) and a $215.23 consensus target. The stock shows bullish technical momentum above key support at $162, while fundamentals reveal impressive 75.73% ROE and 11.55% net margin. Recent developments include a $4.2 billion US loan for nuclear expansion and a 20-year power deal with New Era Energy, positioning VST to capitalize on AI-driven electricity demand.
Vistra offers compelling exposure to the AI power infrastructure theme with strong profitability and government backing, though investors face earnings volatility risks as seen in recent quarterly misses. The stock trades at a premium valuation (P/E 26.33) but maintains upside potential if execution on nuclear expansion and data center contracts meets expectations.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →